How Precision Medicine Uses Genomics and Biomarkers to Guide Healthcare

How Precision Medicine Uses Genomics and Biomarkers to Guide Healthcare

Precision medicine aims to tailor healthcare decisions to characteristics that differ among individuals and diseases. These characteristics may include inherited genetic variants, molecular changes within a tumor, proteins circulating in blood, environmental exposures, lifestyle factors, and clinical history.

The approach does not necessarily mean creating a unique treatment for every person. More often, it involves placing patients or diseases into biologically meaningful subgroups. Clinicians can then use those classifications to select tests, estimate risk, choose therapies, adjust doses, or monitor whether treatment is working.

Genomics and biomarkers are central to this process. Genomics provides information about DNA and its activity, while biomarkers offer measurable indicators of biological states or responses. Used together—and interpreted alongside symptoms, imaging, pathology, and other clinical information—they can make some healthcare decisions more specific and evidence-based.

What precision medicine means

Traditional medical decisions often rely on broad categories such as age, symptoms, organ involved, and disease stage. These remain essential, but people with apparently similar conditions may have different underlying biology. As a result, they may respond differently to the same treatment or face different risks of progression and adverse effects.

Precision medicine seeks to account for this variation. Its applications generally fall into several areas:

• Diagnosis: Identifying a disease or distinguishing between conditions with similar clinical features.
• Prognosis: Estimating the likely course of a disease.
• Treatment selection: Identifying therapies more likely to work for a molecularly defined subgroup.
• Dose selection: Adjusting medication use according to genetic or physiological differences.
• Risk assessment: Estimating susceptibility to certain inherited or acquired conditions.
• Monitoring: Measuring response, recurrence, progression, or treatment-related toxicity.

Not every healthcare decision benefits from molecular testing. A precision approach is most useful when a genomic result or biomarker has been analytically validated, associated with a clinically relevant outcome, and shown to improve or meaningfully inform care.

Genomics: examining DNA and gene activity

Genomics is the study of an organism’s complete genetic material and the interactions among genes. In healthcare, genomic testing can examine inherited DNA, acquired genetic changes, or patterns of gene activity.

Inherited, or germline, variation

Germline variants are present in the egg or sperm and therefore usually occur in nearly every cell of the body. Some variants can increase the likelihood of particular diseases or explain an existing condition.

Testing for germline variation may be used to:

• Diagnose certain rare genetic disorders.
• Evaluate inherited cancer susceptibility.
• Clarify familial cardiovascular or neurological conditions.
• Identify carrier status for selected recessive disorders.
• Inform medication choice or dosing through pharmacogenomics.

A germline result may also have implications for biological relatives. However, carrying a risk-associated variant does not always mean that disease will develop. Its significance can depend on the specific gene, the variant, age, family history, environmental exposures, and other genetic factors.

Acquired, or somatic, variation

Somatic variants arise during a person’s lifetime and are present only in some cells. Cancer is the leading clinical setting in which these changes are routinely examined. Tumor cells can acquire alterations that promote growth, impair DNA repair, or help the cancer evade immune responses.

Tumor genomic testing may identify:

• Mutations that can be targeted by a particular drug.
• Molecular features associated with sensitivity or resistance.
• Alterations that help classify a tumor more precisely.
• Changes that provide prognostic information.
• Potential eligibility for a clinical trial.

A variant found in a tumor is not automatically inherited. If a tumor result suggests a possible germline alteration, separate testing of non-tumor tissue may be needed to determine whether it is present throughout the body.

Gene expression and other layers of biology

DNA sequence is only one source of information. Cells also regulate which genes are active and how strongly they are expressed. Tests may therefore assess RNA, patterns of gene expression, epigenetic modifications, proteins, or metabolites.

These molecular layers can reveal biological activity that DNA sequencing alone may not capture. For example, a gene may be structurally intact but unusually active, silenced, or affected by changes elsewhere in a biological pathway.

What biomarkers are

A biomarker is a measurable characteristic that indicates a biological process, disease state, or response to an intervention. Biomarkers are broader than genetic tests. They can include molecules, physiological measurements, imaging findings, and features observed in tissue.

Common categories include:

One biomarker can sometimes serve more than one purpose. Its meaning depends on the clinical context, the method used to measure it, and the evidence supporting a particular interpretation.

How genomic and biomarker information guides care

Precision medicine generally follows a sequence from sample collection to clinical interpretation.

1. Defining the clinical question

Testing is most useful when it addresses a specific decision. The question might be whether a person has an inherited disorder, whether a tumor contains a treatable alteration, or whether a medication is likely to be metabolized unusually quickly or slowly.

The intended use determines which specimen, technology, and test scope are appropriate.

2. Collecting a suitable sample

Genomic material and biomarkers can be measured in:

• Blood
• Saliva
• Buccal cells from inside the cheek
• Tumor tissue
• Bone marrow
• Urine
• Cerebrospinal fluid
• Other body fluids or tissue samples

Sample quality matters. Tumor specimens, for example, may contain a mixture of cancer cells and normal cells. The proportion of tumor material can affect whether an alteration is detected.

3. Measuring molecular features

Testing methods vary in scope. A targeted assay may examine one variant or a small set of genes. A multigene panel covers a broader group associated with a particular condition. Exome sequencing focuses mainly on protein-coding regions, while genome sequencing assesses a wider range of DNA.

Other technologies measure RNA expression, proteins, metabolites, chromosome changes, or chemical modifications to DNA. No single method detects every type of alteration equally well.

4. Classifying the result

Finding a genomic variant is not the same as proving that it causes disease or predicts treatment response. Laboratories evaluate evidence such as:

• How common the variant is in relevant populations.
• Whether it changes a protein or gene-regulatory region.
• Whether it has been observed in people with the condition.
• Results from functional studies.
• Patterns of inheritance within families.
• Associations with treatment response or resistance.

For inherited conditions, variants are commonly classified along a spectrum that includes benign, likely benign, uncertain significance, likely pathogenic, and pathogenic. A variant of uncertain significance does not provide the same evidence as a pathogenic variant and usually should not be treated as a definitive explanation.

5. Integrating the result with clinical evidence

Molecular findings are interpreted alongside other information, including:

• Symptoms and physical findings
• Family and medical history
• Pathology
• Imaging
• Disease stage and severity
• Previous treatment
• Kidney and liver function
• Other medications
• Patient preferences and practical circumstances

This integration is crucial because a molecular result may be technically accurate without being clinically actionable.

Established applications

Cancer diagnosis and treatment

Oncology is one of the most developed areas of precision medicine. Cancers arising in the same organ can have different molecular drivers, while tumors from different organs may sometimes share a targetable feature.

Biomarker testing can help:

• Refine tumor classification.
• Identify molecular targets for approved treatments.
• Estimate whether selected immunotherapies are more or less likely to help.
• Detect mechanisms of drug resistance.
• Monitor disease using imaging, proteins, cells, or tumor-derived genetic material.
• Identify clinical trials organized around a molecular alteration.

The presence of a target does not guarantee that a therapy will work. Response can depend on the tumor type, other genomic changes, prior treatment, disease distribution, and the biological role of the alteration. Tumors can also evolve under treatment pressure, leading to resistance or differences among metastatic sites.

Rare and inherited diseases

Genomic sequencing can shorten the diagnostic process for some people with suspected rare disorders, especially when symptoms involve multiple organ systems or do not fit a familiar syndrome.

A molecular diagnosis may:

• Explain the cause of a condition.
• Clarify inheritance and recurrence risk.
• Reduce the need for further diagnostic procedures.
• Direct surveillance for known complications.
• Identify a condition-specific therapy in selected cases.
• Connect patients with research studies or condition-specific resources.

Even broad sequencing does not resolve every case. The causal change may be difficult for the chosen technology to detect, may occur outside well-understood regions, or may involve a gene not yet linked to human disease.

Pharmacogenomics

Pharmacogenomics examines how inherited genetic variation affects medication response. Variants can influence drug-metabolizing enzymes, transport proteins, immune reactions, or drug targets.

Depending on the medication and clinical setting, pharmacogenomic information may support:

• Selection of an alternative drug.
• A different starting dose.
• Closer monitoring.
• Avoidance of a medication associated with a serious reaction in genetically susceptible people.

Genetics is only one determinant of medication response. Age, organ function, diet, adherence, interactions with other drugs, and the underlying disease can be equally or more important. The usefulness of testing also varies considerably among medications.

Infectious disease

Precision approaches can characterize both the patient and the infectious organism. Molecular testing can identify pathogens, distinguish strains, and detect genetic features associated with antimicrobial resistance.

Host biomarkers may also help characterize inflammation or immune response. However, translating those signals into reliable treatment decisions requires careful validation because immune responses vary over time and can overlap among different infections and noninfectious conditions.

Cardiovascular and metabolic conditions

Some cardiovascular disorders have strong inherited components, including selected cardiomyopathies, rhythm disorders, and lipid conditions. Genomic findings can support diagnosis and family screening when interpreted with clinical evaluation.

For common diseases such as hypertension or type 2 diabetes, genetics generally contributes alongside many environmental and behavioral factors. Molecular information may improve risk models in some contexts, but it does not replace established measures such as blood pressure, cholesterol, glucose regulation, smoking exposure, or family history.

Biomarkers for monitoring disease

Repeated biomarker measurements can reveal change over time. This is different from a one-time diagnostic or risk test.

Monitoring may involve:

• Measuring a circulating protein.
• Tracking blood cell populations.
• Repeating molecular testing after treatment.
• Assessing residual disease after an apparent response.
• Looking for emerging resistance alterations.
• Combining laboratory values with imaging and symptoms.

Trends are often more informative than isolated values, but interpretation requires consistency. Different laboratories, assay platforms, sample conditions, and collection times can produce results that are not directly comparable.

So-called liquid biopsy methods analyze material released into blood or other fluids, such as cell-free DNA. These approaches can sometimes provide molecular information without an invasive tissue biopsy. Their sensitivity varies with tumor type, disease burden, location, and assay design, so a negative result may not establish that a relevant alteration is absent.

What makes a test clinically useful?

A useful precision medicine test must meet more than one standard.

Analytical validity

Analytical validity describes whether the test accurately and reliably measures what it claims to measure. Relevant features include sensitivity, specificity, reproducibility, and limits of detection.

Clinical validity

Clinical validity asks whether the measured feature is associated with a disease, prognosis, treatment response, or other outcome in the population being tested.

Clinical utility

Clinical utility addresses whether using the result leads to a meaningful benefit in decision-making or outcomes. A test may accurately detect a biological difference but still have limited utility if the result does not change management.

Actionability

An actionable result has a supported next step, such as a validated treatment, surveillance strategy, preventive intervention, or confirmatory test. Actionability is context-dependent and may change as evidence and treatment options develop.

Important limitations

Results can be uncertain

Genomic knowledge is incomplete. Some variants cannot be confidently classified, and classifications may change as additional evidence becomes available. Reanalysis can occasionally provide new answers, particularly in rare disease genomics.

Association does not always establish causation

A biomarker may correlate with disease without causing it. It can also appear predictive in one study but perform poorly in another population or clinical setting. Independent validation is therefore important.

Disease biology changes over time

Cancer and some other diseases evolve. A sample collected at diagnosis may not fully represent the biology after several treatments or at a different disease site.

Tests can miss relevant changes

Targeted panels examine only selected regions. Broader sequencing still has technical blind spots and may not reliably detect every repeat expansion, structural alteration, low-level mosaic change, epigenetic abnormality, or complex genomic region.

Incidental findings may emerge

Broad testing can identify information unrelated to the original clinical question, including inherited disease risks or biological relationships. Consent processes should address the possibility of secondary findings and preferences about receiving them.

A negative result is not always reassuring

A negative test may mean that no relevant alteration was found with the method used. It does not necessarily exclude genetic susceptibility, eliminate disease risk, or show that a biomarker-guided therapy cannot work.

Equity and representation

Precision medicine depends on reference datasets that connect molecular variation with health outcomes. If these datasets underrepresent particular ancestry groups or communities, interpretation can be less accurate for those populations. This may increase uncertain results or weaken risk estimates.

Equitable implementation requires attention to:

• Diversity in research participation.
• Access to high-quality testing and specialist interpretation.
• Affordability of tests and linked treatments.
• Language-appropriate consent and education.
• Availability outside major academic centers.
• Community engagement and governance.
• Whether a test improves outcomes in the population where it will be used.

A technologically advanced test does not promote equity by itself. Its value depends on who can access it, how well it performs across populations, and whether the result leads to realistic care options.

Privacy and responsible data use

Genomic data are identifying and may reveal information about biological relatives. They can also remain useful for research and reinterpretation long after the original test.

Responsible use involves clear policies concerning:

• Who can access the data.
• How long samples and records are stored.
• Whether data may be used for research.
• Whether results can be reanalyzed.
• How findings are shared with relatives.
• How cybersecurity risks are managed.
• Whether participants can withdraw from certain uses.

De-identification can reduce privacy risks but may not remove them entirely, particularly when genomic data are combined with other information.

The role of multidisciplinary expertise

Precision medicine often requires collaboration among clinicians, laboratory specialists, pathologists, genetic counselors, pharmacists, bioinformaticians, and data scientists.

Their roles may include:

• Selecting the appropriate test.
• Confirming that a sample is adequate.
• Assessing technical quality.
• Interpreting variants and biomarkers.
• Matching findings with evidence and treatment options.
• Explaining inherited implications.
• Reassessing results as knowledge changes.

In oncology, molecular tumor boards sometimes bring these perspectives together for complex cases. Similar collaborative models are used in rare disease diagnosis and pharmacogenomics.

Where the field is heading

Precision medicine is expanding beyond single genes and single biomarkers. Emerging strategies combine multiple layers of data, including genomics, RNA, proteins, metabolites, imaging, wearable-device measurements, and longitudinal health records.

Potential developments include:

• Better detection of early molecular changes.
• More accurate classification of biologically distinct disease subtypes.
• Improved monitoring through minimally invasive samples.
• Real-time identification of treatment resistance.
• More systematic use of pharmacogenomic information.
• Risk models that integrate molecular, environmental, and clinical factors.

These approaches also create challenges. Complex models can be difficult to validate, may reproduce biases in their training data, and may not transfer reliably between healthcare systems or populations. Greater data volume does not automatically produce better care; the information must be accurate, interpretable, relevant, and linked to an effective action.

A tool for better-defined decisions

Genomics and biomarkers have changed how some diseases are diagnosed, classified, treated, and monitored. Their greatest value lies in refining specific healthcare decisions—not in replacing clinical judgment or reducing a person to a molecular profile.

A successful precision medicine strategy connects a clearly defined question with a validated test, careful interpretation, and an intervention supported by evidence. When those elements align, molecular information can help identify meaningful differences among patients and diseases. When they do not, additional testing may add uncertainty rather than precision.